临床试验结局为何未能转化为患者获益
本文探讨临床试验结局指标存在的问题,包括使用替代、复合和主观终点,忽视患者视角,发表偏倚与结局报告偏倚(含不良事件报告不足),侧重相对测量而忽视绝对结局,报告误导,结局多重性及核心结局集缺失,这些问题使证据难以解读并阻碍研究转化为实践与政策。
要点
- 试验结局应评估真实反映现实环境和患者关切的结果,但许多试验未达此要求。
- 结局问题包括替代/复合/主观终点、忽视患者视角、发表与报告偏倚、相对测量优先等。
- 结局可基于患者视角开发,并做到完整、透明、胜任地报告。
核心结论
- 临床试验结局存在多种问题,使证据难以或无法解读,并削弱研究向实践和政策的转化。
研究设计与样本
- 本文为观点性文章,未报告系统检索范围或样本量。
主要发现
- 试验结局问题包括使用替代、复合和主观终点,设计研究结局时未考虑患者视角。
- 存在发表和其他结局报告偏倚,包括不良事件报告不足。
- 报告相对测量而牺牲信息更丰富的绝对结局,存在误导性报告、结局多重性及核心结局集缺失。
临床怎么用
- 作者认为试验结局可基于患者视角开发,并做到完整、透明、胜任地报告。
- 作者认为临床医生、患者、研究人员及卫生服务支付者有权要求可靠证据证明干预是否改善患者相关临床结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical research should ultimately improve patient care. For this to be possible, trials must evaluate outcomes that genuinely reflect real-world settings and concerns. However, many trials continue to measure and report outcomes that fall short of this clear requirement. We highlight problems with trial outcomes that make evidence difficult or impossible to interpret and that undermine the translation of research into practice and policy. These complex issues include the use of surrogate, composite and subjective endpoints; a failure to take account of patients' perspectives when designing research outcomes; publication and other outcome reporting biases, including the under-reporting of adverse events; the reporting of relative measures at the expense of more informative absolute outcomes; misleading reporting; multiplicity of outcomes; and a lack of core outcome sets. Trial outcomes can be developed with patients in mind, however, and can be reported completely, transparently and competently. Clinicians, patients, researchers and those who pay for health services are entitled to demand reliable evidence demonstrating whether interventions improve patient-relevant clinical outcomes.
引用
- Heneghan C, Goldacre B, Mahtani KR, et al. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017. PMID: 28288676. doi:10.1186/s13063-017-1870-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。